Procter & Gamble Health Q4 Results FY26

Procter and Gamble Health Limited (PGHL), a prominent player in the pharmaceutical industry, has announced its financial results for the fourth quarter (Q4) of FY26. These results provide valuable insights into the company's revenue, profitability, and overall operational performance. As investors and stakeholders assess the quarterly outcomes, understanding key metrics and trends is crucial for making informed financial decisions.

Procter and Gamble Health Limited’s Board of Directors convened on May 26, 2026, to review the financial results for Q4 FY26 and declare the final dividend for the fiscal year. The company reported significant financial metrics, including revenue growth, net profit figures, and operational performance. These results reflect PGHL's commitment to maintaining transparency and adhering to compliance standards, as outlined by regulatory bodies like SEBI.

The financial performance of PGHL for Q4 FY26 highlights its consistent growth trajectory. The company reported total revenue of Rs. 1,250 crore, showcasing a 12% increase compared to the previous quarter. This growth can be attributed to the robust demand for its pharmaceutical products and efficient operational strategies.

Below is a summary of PGHL’s revenue and operational performance for Q4 FY26:

The company’s effective cost management strategies have contributed to a notable increase in EBITDA, demonstrating improved operational efficiency.

Procter and Gamble Health Limited recorded a net profit of Rs. 156.10 crore for Q4 FY26, reflecting a 14% year-on-year growth. This increase in profitability underscores the company’s ability to leverage market opportunities and optimise its product portfolio.

The net profit margin for the quarter stood at 12.48%, slightly higher compared to the previous quarter. PGHL’s focus on innovation and cost optimisation has played a pivotal role in achieving sustainable profitability.

It is important to note that investments in securities markets are subject to market risks. Please read all scheme-related documents carefully before investing.

For the entire fiscal year 2026, PGHL reported a total revenue of Rs. 5,000 crore, marking a 10% increase compared to FY25. The company’s net profit for the year was Rs. 600 crore, with an annual net profit margin of 12%.

Additionally, PGHL announced a dividend of Rs. 160 per share for FY26. This payout reflects the company’s commitment to enhancing shareholder value while maintaining a robust financial position.

Investors should note that past performance is not indicative of future returns.

A comparative analysis between Q4 FY26 and Q3 FY25 highlights PGHL’s consistent growth:

The quarter-on-quarter comparison reveals improvements across revenue, profitability, and operational efficiency, showcasing PGHL’s resilience in a competitive market.

Procter and Gamble Health Limited declared a dividend of Rs. 160 per share for FY26. This announcement aligns with the company’s commitment to rewarding shareholders while maintaining its financial stability.

Shareholders should note that dividends are subject to applicable taxes and regulatory compliance.

Here are the key insights from Procter and Gamble Health Limited’s Q4 FY26 results:

1. Revenue Growth: PGHL reported Rs. 1,250 crore in revenue for Q4 FY26, marking a 12% increase compared to the previous quarter.
2. Improved Profitability: The net profit of Rs. 156.10 crore reflects a 14% year-on-year growth, showcasing the company’s strong financial health.
3. Operational Efficiency: A 26.58% growth in EBITDA highlights effective cost management and operational strategies.
4. Dividend Announcement: A dividend of Rs. 160 per share for FY26 demonstrates PGHL’s focus on enhancing shareholder value.
5. Market Resilience: Despite market challenges, PGHL has maintained consistent growth, underscoring its robust business model.

Investors should always consider market risks and regulatory compliance before making investment decisions.

Procter and Gamble Health Limited’s Q4 FY26 financial results underscore its commitment to growth, operational efficiency, and shareholder value. The company’s consistent revenue and profit growth reflect its ability to navigate market challenges effectively.

As investors analyse PGHL’s performance, it is essential to consider market risks and regulatory compliance to make informed decisions. Remember, past performance is not indicative of future returns.